Evidence map›Paper›PMID 36856861›Full record

ArticleActa diabetologica2023

Haptoglobin genotype and its relation to asymptomatic cerebral small-vessel disease in type 1 diabetes.

M I Eriksson, A Syreeni, N Sandholm, E H Dahlström, D Gordin, T Tatlisumak, J Putaala, Per-Henrik Groop, J Martola, L M Thorn and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta diabetologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 4 countries.

M I ErikssonFolkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
A SyreeniFolkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
N SandholmFolkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
E H DahlströmFolkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
D GordinDepartment of Nephrology, University of Helsinki and Helsinki University Hospital, Biomedicum Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.
T TatlisumakNeurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
J PutaalaNeurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Per-Henrik GroopFolkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland. per-henrik.groop@helsinki.fi.ORCID http://orcid.org/0000-0003-4055-6954
J MartolaDepartment of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
L M ThornFolkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
FinnDiane Study Group
University of Helsinki · FIJoslin Diabetes Center · USKarolinska University Hospital · SE

Funding

Academy of Finland 275614Academy of Finland 316664Academy of Finland UAK10121MRINovo Nordisk Fonden NNF OC0013659
6 · The paper itself

Abstract

aimCerebral small-vessel disease (SVD) is prevalent in type 1 diabetes and has been associated with the haptoglobin variant allele Hp1. Contrarily, the Hp2-allele has been linked to cardiovascular disease and the role of haptoglobin-genotype in asymptomatic SVD is unknown. We, therefore, aimed to evaluate the alleles' association with SVD.

methodsThis cross-sectional study included 179 neurologically asymptomatic adults with type 1 diabetes (women 53%, mean age 39 ± 7 years, diabetes duration 23 ± 10 years, HbA

resultsSVD prevalence was 34.6%. Haptoglobin genotype frequencies were 15.6% (Hp1-1), 43.6% (Hp1-2), and 40.8% (Hp2-2). Only diastolic blood pressure differed between the genotypes Hp1-1, Hp1-2, and Hp2-2 (81 [74-83], 75 [70-80], and 75 [72-81] mmHg, p = 0.019). Haptoglobin genotype frequencies by presence versus absence of SVD were 16.1%; 46.8%; 37.1% versus 15.4%; 41.9%; 42.7% (p = 0.758). Minor allele frequencies were 39.5% versus 36.3% (p = 0.553). Hp1 homozygotes and Hp2 carriers displayed equal proportions of SVD (35.7% vs 34.4%, p > 0.999) and SVD manifestations (white matter hyperintensities 14.3% vs 17.9%, p = 0.790; microbleeds 25.0% vs 21.9%, p = 0.904; lacunar infarcts 0% vs 3.6%, p > 0.999). Hp1-1 was not associated with SVD (OR 1.19, 95% CI 0.46-2.94, p = 0.712) when adjusting for age, blood pressure, and diabetic retinopathy.

conclusionsAlthough the SVD prevalence was high, we detected no significant association between SVD and haptoglobin-genotype.

Indexed as

Cerebral Small Vessel DiseasesDiabetes Mellitus, Type 1Stroke, LacunarAdultCerebral HemorrhageChromosomal Proteins, Non-HistoneCross-Sectional StudiesFemaleGenotypeHaptoglobinsHumansMiddle AgedChromosomal Proteins, Non-HistoneHaptoglobinsBrain MRICerebral small-vessel diseaseDiabetes mellitusHaptoglobin genotypeStrokeType 1 diabetes

Identifiers

PMID36856861
PMCPMC10148779
OpenAlexW4322719160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.